Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Patel

Showing results (131-140 of 152) with videos related to

Pageof 16
Sort By:
Journal of Medicinal Chemistry|August 6, 2008
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonistsYuan Cheng, Brian K Albrecht, James Brown, et al.
Burns : Journal of the International Society for Burn Injuries|April 9, 2021
Measuring the impact of burn injury on the parent-reported health outcomes of children 1-to-5 years: Item pool development for the Preschool<sub>1-5</sub> Life Impact Burn Recovery Evaluation (LIBRE) ProfileGabrielle G Grant, Keri J S Brady, Frederick J Stoddard, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitorsBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure-Based Design of Potent and Selective CK1γ InhibitorsHongbing Huang, Lisa Acquaviva, Virginia Berry, et al.
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinaseVictor J Cee, Alan C Cheng, Karina Romero, et al.
Journal of Medicinal Chemistry|August 19, 2007
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitorsMichele H Potashman, James Bready, Angela Coxon, et al.
Journal of Medicinal Chemistry|March 4, 2008
Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesisDaniel S La, Julie Belzile, James V Bready, et al.
Journal of Medicinal Chemistry|January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinaseVictor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Journal of Medicinal Chemistry|January 27, 2007
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitorBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
Journal of Medicinal Chemistry|May 14, 2015
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell linesStephanie Geuns-Meyer, Victor J Cee, Holly L Deak, et al.
Pageof 16

Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
Journal of Medicinal Chemistry|August 6, 2008
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonistsYuan Cheng, Brian K Albrecht, James Brown, et al.
Burns : Journal of the International Society for Burn Injuries|April 9, 2021
Measuring the impact of burn injury on the parent-reported health outcomes of children 1-to-5 years: Item pool development for the Preschool<sub>1-5</sub> Life Impact Burn Recovery Evaluation (LIBRE) ProfileGabrielle G Grant, Keri J S Brady, Frederick J Stoddard, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitorsBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure-Based Design of Potent and Selective CK1γ InhibitorsHongbing Huang, Lisa Acquaviva, Virginia Berry, et al.
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinaseVictor J Cee, Alan C Cheng, Karina Romero, et al.
Journal of Medicinal Chemistry|August 19, 2007
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitorsMichele H Potashman, James Bready, Angela Coxon, et al.
Journal of Medicinal Chemistry|March 4, 2008
Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesisDaniel S La, Julie Belzile, James V Bready, et al.
Journal of Medicinal Chemistry|January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinaseVictor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Journal of Medicinal Chemistry|January 27, 2007
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitorBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
Journal of Medicinal Chemistry|May 14, 2015
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell linesStephanie Geuns-Meyer, Victor J Cee, Holly L Deak, et al.
Pageof 16